Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueNotes PayablesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ascendis Pharma A (ASND) Receivables: 2012-2025

Historic Receivables for Ascendis Pharma A (ASND) over the last 11 years, with Sep 2025 value amounting to $168.7 million.

  • Ascendis Pharma A's Receivables rose 217.68% to $168.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $569.7 million, marking a year-over-year increase of 110.22%. This contributed to the annual value of $190.1 million for FY2024, which is 221.46% up from last year.
  • Ascendis Pharma A's Receivables amounted to $168.7 million in Q3 2025, which was up 25.80% from $134.1 million recorded in Q2 2025.
  • Ascendis Pharma A's 5-year Receivables high stood at $187.7 million for Q4 2024, and its period low was $8.7 million during Q1 2021.
  • For the 3-year period, Ascendis Pharma A's Receivables averaged around $87.9 million, with its median value being $73.8 million (2024).
  • In the last 5 years, Ascendis Pharma A's Receivables dropped by 18.09% in 2022 and then skyrocketed by 217.68% in 2025.
  • Quarterly analysis of 5 years shows Ascendis Pharma A's Receivables stood at $25.5 million in 2021, then decreased by 1.01% to $25.2 million in 2022, then skyrocketed by 134.30% to $59.1 million in 2023, then surged by 217.38% to $187.7 million in 2024, then surged by 217.68% to $168.7 million in 2025.
  • Its Receivables stands at $168.7 million for Q3 2025, versus $134.1 million for Q2 2025 and $79.1 million for Q1 2025.